文献速递消化系统肿瘤

阿帕替尼联合多西他赛二线治疗晚期胃癌的临床研究进展总结

[Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究纳入23例一线化疗失败的晚期胃癌患者,给予阿帕替尼联合多西他赛治疗,20例可评价疗效,客观缓解率20.0%,疾病控制率85.0%,中位无进展生存4.5个月,主要不良反应为高血压、呕吐和乏力,结论认为该方案安全有效。

要点

  • 阿帕替尼联合多西他赛二线治疗晚期胃癌的客观缓解率为20.0%。
  • 疾病控制率达85.0%,中位无进展生存期为4.5个月。
  • 主要不良反应为高血压、呕吐和乏力,安全性良好。

核心结论

  • 阿帕替尼联合多西他赛二线治疗一线化疗失败的晚期胃癌患者具有生存获益且安全性良好。

研究设计与样本

  • 回顾性收集2017年3月至2018年5月山西省肿瘤医院23例一线化疗(非多西他赛或紫杉醇)失败后接受阿帕替尼联合多西他赛治疗的晚期胃癌患者临床资料。

主要发现

  • 20例可评价疗效患者中部分缓解4例、稳定13例、进展3例。
  • 客观缓解率为20.0%,疾病控制率为85.0%,中位无进展生存时间为4.5个月。
  • 不良反应以高血压、呕吐和乏力为主。

临床怎么用

  • 对于一线化疗失败的晚期胃癌患者,可考虑阿帕替尼联合多西他赛作为二线治疗选择。

局限性

  • 样本量较小(23例),仅20例可评价疗效,且为单中心回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the progression-free survival (PFS) and safety of apatinib combined with docetaxel treated patients with advanced gastric cancer after failure of first-line chemotherapy. Methods: From March 2017 to May 2018, 23 patients with advanced gastric cancer who had received a failure of first-line chemotherapy (either fedocetaxel or paclitaxel) were treated with apatinib combined with docetaxel. The short-term efficacy and safety of the patients were observed. Results: The therapeutic effects of 20 patients were evaluated. Among them, 4 cases were partial response (PR), 13 patients were stable disease (SD), 3 patients were progressive disease (PD). The objective remission rate (ORR) was 20.0%, the disease control rate (DCR) was 85.0%, the median PFS (mPFS) was 4.5 months. The main adverse reactions were hypertension, vomiting and weakness. Conclusion: Apatinib combined with docetaxel applied in the second-line treatment of gastric cancer is safe and effective. 目的: 分析甲磺酸阿帕替尼联合多西他赛治疗一线化疗失败后晚期胃癌患者的近期疗效及安全性。 方法: 收集2017年3月至2018年5月就诊于山西省肿瘤医院、采用一线化疗方案(非多西他赛或紫杉醇)治疗失败后的23例晚期胃癌患者的临床资料,给予阿帕替尼联合多西他赛治疗,分析患者的近期疗效和安全性。 结果: 23例患者中,20例患者可评价疗效,其中部分缓解4例,稳定13例,疾病进展3例;客观缓解率为20.0%,疾病控制率为85.0%,中位无进展生存时间为4.5个月。不良反应以高血压、呕吐和乏力为主。 结论: 阿帕替尼联合多西他赛二线治疗晚期胃癌患者具有生存获益,安全性良好。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang MD, Gao J, Liu XL, et al. [Summary of clinical research progression of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32842450. doi:10.3760/cma.j.cn112152-20190121-00027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。